Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal
Executive Summary
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
You may also be interested in...
Investors Cool On Seagen As Merck & Co Merger Hopes Fade
After more than three months of speculation about a possible Merck & Co buyout, the chatter has gone quiet – but the deal might not be dead yet.
Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop
Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.
Seagen Aims To Make Tukysa First Drug For HER2-Positive Colorectal Cancer
The Phase II MOUNTAINEER trial showed a benefit for patients with HER2-positive metastatic colorectal cancer treated with the tyrosine kinase inhibitor in combination with trastuzumab.